We love to hear from our listeners. Send us a message.
Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's been drawing from her immersion in both the business and science disciplines as President & CEO at Meira GTx. On this episode of the Business of Biotech, Dr. Forbes and I go into deep analysis mode as we examine the risks she's taken in her current role, and how she applies her experiences – both good and bad – with handling other people's money to building a biotech company.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
